Effect of Helicobacter pylori eradication on glycaemia control in patients with type 2 diabetes mellitus and comparison of two therapeutic regimens

Vafaeimanesh, Jamshid; Rajabzadeh, Rabeah; Ahmadi, Anahita; Moshtaghi, M; Banikarim, Seyed-Amir; Hajiebrahimi, Shahin; Seyyedmajidi, Mohammadreza

doi:10.1016/j.ajg.2013.03.002

Cited by 27 publications

(36 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“… did not demonstrate any positive association between H. pylori infection and DM, in contrast to some viruses such as EBV and HHV6, while Vafaeimanesh et al. showed that H. pylori eradication plays no role in the control of glycemia in type 2 DM patients. Similarly, Wada et al.…”

Section: Diabetes Mellitusmentioning

confidence: 93%

“…Jafarzadeh et al [18] reported a similar H. pylori infection rate between type 2 DM and nondiabetic controls (76% vs 75%), while the anti-H. pylori IgG titer was significantly higher in nondiabetic subjects compared with DM patients (131.63 AE 11.68 vs 54.43 AE 4.50 U/ mL, p < .0001). Haeseker et al [19] did not demonstrate any positive association between H. pylori infection and DM, in contrast to some viruses such as EBV and HHV6, while Vafaeimanesh et al [20] showed that H. pylori eradication plays no role in the control of glycemia in type 2 DM patients. Similarly, Wada et al [21] found that H. pylori eradication did not affect glycemic control in Japanese patients with type 2 DM, at least during the 6-month observational period.…”

Section: Diabetes Mellitusmentioning

confidence: 97%

See 1 more Smart Citation

Helicobacter pylori and Extragastric Diseases

Franceschi¹,

Tortora

Gasbarrini³

et al. 2014

Helicobacter

127

View full text Add to dashboard Cite

While Helicobacter pylori infection was initially revealed to be associated only with some gastroduodenal diseases, further studies have shown its possible role in several extragastric diseases. For idiopathic thrombocytopenic purpura, sideropenic anemia, and vitamin B12 deficiency, the diagnosis of H. pylori infection is recommended, and there are many other conditions such as cardiovascular, neurological, dermatological, and respiratory diseases in which H. pylori may possibly play a role. Interestingly, a potential role has also been described for GI neoplastic diseases, including colorectal and pancreatic cancer. Different mechanisms of action have been proposed, ranging from the induction of a low grade inflammatory state to the occurrence of molecular mimicry mechanisms. This review summarizes the results of the most relevant studies published on this topic over the last year.

show abstract

Section: Diabetes Mellitusmentioning

confidence: 93%

Section: Diabetes Mellitusmentioning

confidence: 97%

Helicobacter pylori and Extragastric Diseases

Franceschi¹,

Tortora

Gasbarrini³

et al. 2014

Helicobacter

127

View full text Add to dashboard Cite

show abstract

“…According to a report card grading of H. pylori therapy (Graham et al, 2007; Graham and Dore, 2016), the efficacy of BQTs is good or fair in most studies conducted in China and Taiwan (Sun et al, 2010; Liang et al, 2013; Xie et al, 2014; Zhang W. et al, 2015; Liou et al, 2016), with the intention-to-treat (ITT) analysis showing an efficacy above 85% and the per protocol (PP) analysis showing an efficacy above 90%. However, some studies in Iran and Turkey reported variable results with triple therapies plus bismuth (Sezgin et al, 2006; Uygun et al, 2008; Minakari et al, 2010; Vafaeimanesh et al, 2013). This discrepancy might be explained by differences in the prevalence of resistance, the cure rate of resistant infections or both.…”

Section: Treatmentmentioning

confidence: 99%

Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance

Zhu

Lü

2017

Front. Cell. Infect. Microbiol.

130

View full text Add to dashboard Cite

Helicobacter pylori (H. pylori) is a common gastrointestinal bacterial strain closely associated with the incidence of chronic gastritis, peptic ulcers, gastric mucosa-associated lymphoid tissue lymphoma, and gastric cancer. A current research and clinical challenge is the increased rate of antibiotic resistance in H. pylori, which has led to a decreased H. pylori eradication rate. In this article, we review recent H. pylori infection and reinfection rates and H. pylori resistance to antibiotics, and we discuss the pertinent treatments. A PubMed literature search was performed using the following keywords: Helicobacter pylori, infection, reinfection, antibiotic resistance, bismuth, proton pump inhibitors, vonoprazan, susceptibility, quintuple therapy, dual therapy, and probiotic. The prevalence of H. pylori has remained high in some areas despite the decreasing trend of H. pylori prevalence observed over time. Additionally, the H. pylori reinfection rate has varied in different countries due to socioeconomic and hygienic conditions. Helicobacter pylori monoresistance to clarithromycin, metronidazole or levofloxacin was common in most countries. However, the prevalence of amoxicillin and tetracycline resistance has remained low. Because H. pylori infection and reinfection present serious challenges and because H. pylori resistance to clarithromycin, metronidazole or levofloxacin remains high in most countries, the selection of an efficient regimen to eradicate H. pylori is critical. Currently, bismuth-containing quadruple therapies still achieve high eradication rates. Moreover, susceptibility-based therapies are alternatives because they may avoid the use of unnecessary antibiotics. Novel regimens, e.g., vonoprazan-containing triple therapies, quintuple therapies, high-dose dual therapies, and standard triple therapies with probiotics, require further studies concerning their efficiency and safety for treating H. pylori.

show abstract

“…Because DM has multifactorial pathogenesis, it is difficult to exactly determine the role of H.pylori in pathogenesis. However, a large number of studies, which inform that a significant difference is not seen in terms of glycemic control after the H.pylori eradication treatment, are presented in meta analyses (25)(26)(27). In addition, neuropathy incidence has been detected to be higher in diabetics with H.pylori infection.…”

Section: Introductionmentioning

confidence: 99%

The relationship of H.pylori infection with certain common diseases in the society

Bilman¹

2017

IJMSCI

View full text Add to dashboard Cite

H. pylori is a gram negative bacterium which settles in the stomach mucosa and causes inflammation and infection. The infection is strongly related to duodenal ulceration, gastric ulceration, and from time to time gastric carcinoma. There are many studies in which the relationship between the infection of this quite old but current bacterium in stomach /duodenum and different extra-intestinal diseases has been investigated. Among the extra-intestinal diseases, the most common are asthma, rosacea, chronic idiopathic urticarial, atopy, coronary heart disease and migraine. In this review, it has been aimed to study the data obtained from the fields in this field, and the results have been assessed.

show abstract

Effect of Helicobacter pylori eradication on glycaemia control in patients with type 2 diabetes mellitus and comparison of two therapeutic regimens

Cited by 27 publications

References 24 publications

Helicobacter pylori and Extragastric Diseases

Helicobacter pylori and Extragastric Diseases

Novel and Effective Therapeutic Regimens for Helicobacter pylori in an Era of Increasing Antibiotic Resistance

The relationship of H.pylori infection with certain common diseases in the society

Contact Info

Product

Resources

About